Page 1,354«..1020..1,3531,3541,3551,356..1,3601,370..»

Try This Jeera And Ajwain Tea To Get Rid Of Bloating, Gas And Acidity Once And For All – Doctor NDTV

Posted: September 26, 2019 at 8:43 am

Jeera and ajwain tea: Constant acidity, gas and bloating giving you a hard time? Give up the pills and try this natural metabolism and digestion boosting drink made with simple kitchen ingredients like jeera and ajwain.

Jeera and ajwain are commonly used ingredients for getting relief from acidity

People who experience acidity regularly know how difficult it can be to cope up with it. Acidity or acid reflux may be caused because of eating large meals or lying down directly after a meal, being overweight, smoking, pregnancy, snacking close to your bedtime, regular consumption of alcohol, caffeinate drinks like tea and coffee, to name a few. The most common symptom of acidity is heartburn-a burning pain or discomfort that can move up to your stomach, to your abdomen and chest. Lifestyle coach Luke Coutinho says that the root cause of acidity, bloating, constipation and other symptoms of indigestion are signs of poor gut health.

In one his recent posts on Instagram, he talks about a metabolism and digestion boosting drink, that can help you get relief from acidity. This drink is simple to be prepared at home. It makes use of some common kitchen ingredients which have been known for their numerous health benefits.

Also read:Does Milk Cause Weight Gain Or Is It Bad For Digestion? Expert Nutritionist Tells Us All

For preparing this drink, you need to take a glass jar and add 1 litre water to it. Add cumin seeds (jeera) (2 tbsp), coriander seeds (1 tsp), fennel seeds (1 tsp) and carom seeds (ajwain) (1 tsp). Leave it overnight and strain.

Jeera and ajwain tea can reduce bloating and acidityPhoto Credit: iStock

Drink this water jeera and ajwain water every day in morning to improve metabolism, digestion and reduce acidity.

Another alternative of having this drink daily is by boiling the mixture left over night, reduce it to half and then consume it like tea. In order to enhance the taste or add some flavour to it, you can add grated ginger, some parsley or lemon to the drink. These ingredients can also enhance the effect of this drink on your metabolism and digestion.

You can add ginger to the tea for additional flavour and effectPhoto Credit: iStock

If you want to sweeten the taste, add some honey or jaggery powder to the ajwain and jeera water or tea.

Also read:Turmeric, Ghee And Black Pepper: The 3 Powerful Kitchen Ingredients For Healthy Digestion And Immunity

Also read:Ayurveda Suggests These 5 Herbs For Better Metabolism, Digestion And Weight Loss

(Luke Coutinho, Holistic Lifestyle Coach - Integrative Medicine)

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

DoctorNDTV is the one stop site for all your health needs providing the most credible health information, health news and tips with expert advice on healthy living, diet plans, informative videos etc. You can get the most relevant and accurate info you need about health problems like diabetes, cancer, pregnancy, HIV and AIDS, weight loss and many other lifestyle diseases. We have a panel of over 350 experts who help us develop content by giving their valuable inputs and bringing to us the latest in the world of healthcare.

See the article here:
Try This Jeera And Ajwain Tea To Get Rid Of Bloating, Gas And Acidity Once And For All - Doctor NDTV

Posted in Integrative Medicine | Comments Off on Try This Jeera And Ajwain Tea To Get Rid Of Bloating, Gas And Acidity Once And For All – Doctor NDTV

Does Fiji hold the key to the next big wellness trend? – the AU review

Posted: September 26, 2019 at 8:43 am

Fiji has long been known as one of the happiest nations in the world a title of no surprise to anyone who has ever landed on that eternally gorgeous archipelago of around 330 islands.

Those who have been most definitely wouldve come across a foul-smelling, questionable-tasting, muddy-looking drink called Kava. Widely known for its remarkable effects said to reduce stress and anxiety, up relaxation, mood and focus, help people sleep and even act as an aphrodisiac, its available just about everywhere across Fiji, from luxury hotels to produce markets.

Extracted from a pepper plant that grows in abundance throughout the islands, Kava has grown from its historical and ceremonial roots into an everyday recreational drink for those who have long benefitted from it. Just step into any village in Fiji and youll no doubt hear about nightly Kava ceremonies after work each day.

Kava has been around for a very long time, though in the past two decades its popularity has extended outside of the Pacific Islands, with a swift proliferation of Kava bars being touted as the new coffee houses in USA, and mammoth markets all over the world constantly showing demand for the natural remedy.

Although, Kava hasnt been without spots of short-lived controversy. It was once incredibly popular in Western Europe, until a ban due to unreliable reports of liver toxicity began circulating. Even Australia has had tight restrictions on natures Xanax, enacted because remote communities would begin to abuse it and mix it with alcohol. Both regulations have since been lifted due to new findings, sprouting a resurgence and possible revolution of sorts.

Fiji Kava as a brand is not necessarily new to Fiji, at least but the impact the company could have on the world is well worth paying close attention to. In establishing a tissue culture lab in Fijis old capital of Levuka, as well as a Kava farm on the island, they are seeking to standardise the natural medicine and possibly change the way the world experiences, and views, Kava.

Specifically, they are focusing on the varietal Noble Kava, a wide-spread species in Fiji that has been shown to have the most desirable set of effects without affecting mental clarity, avoiding the issues caused by other types such as Tudei Kava which is abundant on islands like Vanuatu and often considered less safe as well as sometimes being dubbed two-day thanks to its supposed two-day hangover.

What produces the effects credited to Kava are lipophilic resins found in the root, called Kavalactones. And without getting into the nitty gritty of it all, they have been shown in studies to target the same neurotransmitters (for all my neuropsych heads out there GABA, dopamine, and noradrenaline) as benzos, alcohol, and other commonly used drugs, thereby providing a safe and natural alternative. Thats especially exciting when thought about in terms of an alternative to alcohol, considering the long list of issues surrounding its widespread use.

Fiji Kava have extracted Kava plants into a range of products, which are now available across Australia, New Zealand and, as of 19th October, USA. Were talking capsules and tea bags (with chamomile and peppermint) mostly, both listed as natural/complementary medicines here in Australia. They are available everywhere except in the Northern Territory.

That brings a pretty exciting, non-alcoholic way to relax at the end of the day, distilling a big part of Fijis renowned happiness and calm into a natural medicine. Ive personally found steeping two teabags into a warm cuppa a few hours before bedtime has a very positive effect, and thats coming from someone who has had severe sleeping problems since adolescence.

I havent personally felt the euphoria, but can certainly notice a de-stress effect, and hence understand a bit better why Kava bars are such a massive thing in the U.S at the moment.

Although do note that kava doesnt seem to play well with other drugs. Do not mix it with alcohol and make sure to do your own research before deciding if it is for you. This article should not take the place of professional medical advice. If you want more insight into studies negating the claims that kava is bad for the liver, look up with those done by Australias Jerome Sarris, Professor of Integrative Mental Health and Deputy Director of the NICM integrative medicine research institute at Western Sydney University. He has a particular interest in integrative medicine, nutraceutical psychopharmacology, psychotropic plant medicines (like kava), and lifestyle medicine, so youll find plenty of literature on Fijis gift to the world.

For more information on Fiji Kavas products and to order some online head on over to fijikava.com.

The writer travelled to Fiji as a guest of Fiji Kava. This is not a sponsored post and all opinions belong to the writer.

Feature image: View from a Kava Farm on Levuka. Photo supplied.

Original post:
Does Fiji hold the key to the next big wellness trend? - the AU review

Posted in Integrative Medicine | Comments Off on Does Fiji hold the key to the next big wellness trend? – the AU review

Men of platinum: From CEOs to a new dad, men share the milestones that define success – YourStory

Posted: September 26, 2019 at 8:43 am

Arun Krishnamurthy quit his job at Google to start Environmentalist Foundation of India and went on to restore39 lakes and 28 pondsacross India in just over a decade. A well-known environmentalist today, he says, I grew up next to several lakes and ponds. I have seen them in their best shape and condition. It hurts to witness their exploitation, and I wanted to do what was possible.

All of just 32 years, Arun and his actions are archetypal of the change that is taking place in society the emergence of a new breed of men. Men who are abandoning older definitions of masculinity and redefining success through a set of rare milestones.

The new age man today has identified a new set of defining moments in his everyday life, moments that test and nurture his rare values, moments that become his lifes key milestones. If we take a closer look at this new breed of men (like Arun), you will notice that these milestones are a mark of their rare character. Deciding to quit his comfortable job to launch the eco-movement is not only courageous but reveals his selfless commitment towards a larger good. Values such as courage, humility, commitment to giving back, perseverance and the ability to carry people along to success are defining traits that are making these men stand differentiated. Today, he wants to let his character shine, and make it an inherent part of his identity. He believes that the true character of a man comes through when his journey to success is living proof of the values he stands for.

He acknowledges the milestones that mark the transition from the man he was to the man he becomes through his values. For instance, the time he decided to leave a high-paying job and put faith and all his savings to pursue his passion project a courageous milestone! Or the time he persevered to bounce back after a failure or the time he decided to enrol into a learning program despite featuring on a young achievers list a milestone demonstrative of his humility to learn from anyone and at any time.

Shrish Marnad, a developer at a tech startup, consciously chose to work in a startup as opposed to a large multinational. As a 21-year-old engineer graduate, I got placed in a multinational engineering company. At the same time, I was also offered a position in a growing start-up. Coming from a smaller town, everyone expected me to opt for the former.But, I have always been keen on working on projects that challenge me and help me learn continuously. At that point, it was the start-up that promised me that opportunity. So it came as a surprise to many, initially even to my own family, when I chose to work at the start-up.The 29-year-old says,

Their journey to personal greatness does not stop at professional aspirations. Exercising his characters strength transcends all situations and all relationships.

Abhilash K B, a business development manager, shares,

He adds, As someone who travelled extensively and would be away from home even during the weekends because of work commitments, as someone who didnt think twice about attending industry conferences or shows on the weekends because it piqued my interest, today I stand firm to the decision I took a few months ago. Because that is how important being committed to the family is for me.The new father travels every weekend to his hometown to spend time with his wife and daughter and says theres nothing else he would rather do. The new father says, My daughter makes me a better person.

Dr Shyam Bhat, psychiatrist, Integrative Medicine specialist, and author, points out that this inclination towards milestones based on a value system is more relevant now than ever before. It is inspiring to see men living their values. These men become role models for others, to embody values and action them, and leave a legacy for the current as well as the next generation of men to follow suit.He adds,

When asked what would fit his definition of success, he says, Authenticity is a big part of my value system. It has helped me not only become a better therapist, but also a better person.He adds,And, to see that I can contribute to society meaningfully through my work and find joy in the work I do, makes me feel successful.

There is a common underlying narrative that binds what todays men aspire for. It is to find a purpose and live it, be true to their belief system, choose whats important over whats momentary and leave behind an enduring legacy built on a bedrock of values.

And, Platinum Guild of India celebrates these rare men of character, as they announce their foray into a new category platinum jewellery for men - Men of Platinum.

Originally posted here:
Men of platinum: From CEOs to a new dad, men share the milestones that define success - YourStory

Posted in Integrative Medicine | Comments Off on Men of platinum: From CEOs to a new dad, men share the milestones that define success – YourStory

WSU and UI to cohost arts, humanities and science symposium – WSU News

Posted: September 26, 2019 at 8:43 am

Washington State University and the University of Idaho are teaming up to explore news ways of integrating the arts and humanities with science, technology, engineering, mathematics and medicine (STEMM).

More than 50WSU and UIfaculty and administrators are expected to attend a joint symposium Sept.2627 where they will work together to imagine new pathways for interdisciplinary research and teaching. Registration for the event remains open to any interested participants.

The symposium springs from the 2018 National Academies of Science, Engineering and Medicine (NASEM) report titled, Branches from the Same Tree: The Integration of the Humanities and Arts with Sciences, Engineering, and Medicine in Higher Education. The studyestablishes the value of integrating more STEMMcurricula and labs into the academic programs of students majoring in the humanities and arts, and the value of integrating curricula and experiences in the arts and humanities into college and university STEMMprograms. At the same time, the study expresses a growing concern that disciplinary specialization is poorly calibrated to the challenges and opportunities of the present time.

Meeting these challenges will require new ways of working together, something our two nearby universities are ideally located to support, said Todd Butler, associate dean in WSUs College of Arts and Sciences and director of WSUs new Center for Arts and Humanities. We will need to make connections across state lines and disciplines to provide students and faculty with the most integrative curriculum possible, setting them both up for success in the future.

The symposium will celebrate existing cross-disciplinary efforts at the two universities, identify obstacles to this work, and develop strategies for fostering future collaborations. Reflecting a commitment to cross-campus collaboration, the symposium will begin with an evening reception on Thursday, Sept.26, at 5p.m., in the WSU Lewis Alumni Center in Pullman. A full schedule of panel discussions and breakout sessions will then take place at the UI on Friday, Sept.27, in the Horizon and Aurora room of the Idaho Student Union Building in Moscow.

This symposium is a great opportunity for WSU and UIfaculty to discuss the challenges and opportunities of creating cross-campus partnerships to pursue genuine interdisciplinary work involving the arts and humanities, said Christopher Keane, vicepresident for research.

The symposium is sponsored by a collaboration between the WSU Center for Arts and Humanities, the WSU College of Arts and Sciences, the WSU Office of Research, UIs Office of Research, and UIs College of Letters, Arts and Social Sciences.

Contactcas.adf@wsu.edu for information on attending the reception.Registrationis encouraged for the event on Friday. A detailed agenda is availableonline.

Read the original here:
WSU and UI to cohost arts, humanities and science symposium - WSU News

Posted in Integrative Medicine | Comments Off on WSU and UI to cohost arts, humanities and science symposium – WSU News

Gene Therapy for the Planet | Perspectives | Perspectives – KQED

Posted: September 26, 2019 at 8:41 am

An encounter with gene therapy in action inspires Andrew Lewis to believe that healing a sick planet is within reach but depends on all of us.

At a recent North Bay Bob Dylan tribute, I happened to meet a woman who worked as a biochemist at a Bay Area pharma outfit. She manufactures blood proteins used to treat hemophilia. But as we talked, she excitedly announced that one day her work would go away.

She explained that blood coagulant requires 12 distinct proteins. The genome of hemophiliacs, it turns out, are unable to manufacture protein eight. But its now possible to engineer a virus that contains the missing DNA sequence. And if we introduce the virus to hemophiliac marrow, the DNA of the infected marrow will repair and gain the ability to manufacture the missing protein. It all sounded miraculous and strange - voodoo even.

Musicians picked up their guitars, took seats at the keyboards and drum kit and the lilting chime of Mr. Tambourine man filled the room.

Fifteen months ago, a young Greta Thunberg left school and held a sign outside the Swedish Parliament. She stood alone. Skolstrejk fr Klimatet her sign read. Hardly a year later, millions of young people in hundreds of cities and communities in every corner of the globe gathered to strike for climate change.

Go here to read the rest:
Gene Therapy for the Planet | Perspectives | Perspectives - KQED

Posted in Gene therapy | Comments Off on Gene Therapy for the Planet | Perspectives | Perspectives – KQED

Final Tests Planned into Potential OCMD Gene Therapy, Could Support Trial in Patients – Muscular Dystrophy News

Posted: September 26, 2019 at 8:41 am

Three new animal-model tests of a potential gene therapyfor oculopharyngeal muscular dystrophy (OPMD), known as BB-301, are planned, Benitec Biopharmaannounced. Results are expected tosupport a request for a Phase 1 clinical trial in patients.

OPMD results from a faulty PABPN1 gene, leading to a protein that can form insoluble clumps linked with muscle weakness.

BB-301 uses a DNA-directedRNA interference(ddRNAi) strategy. Delivered via a modified, harmless adeno-associated virus (AAV), the therapy is intended to silence and replace the mutant protein. It suppresses its production and provides a source of normal, or wild-type, protein to target cells.

A 2017 study showedthat this approach significantly reduced the amount of PABPN1 aggregates, restored muscle strength and eased muscle fibrosis (scarring) in mice. Subsequent experiments in cells from OPMD patients confirmed these results.

The preclinical research, to be conducted in a canine disease model, will help to optimize methods of administration, confirm the efficiency of the AAV vector in introducing a healthy gene into key muscle cells, assess optimal dosing, and further characterize toxicological data necessary for regulatory filings and clinical trial design.

According to the company, these three planned dog studies will support the submission of an Investigational New Drug (IND) application, an essential step in getting regulatory approval to start the trial. Pre-IND application meetings with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and Health Canada took place in 2017.

Through our continued focus on BB-301 for the treatment of [OPMD], our team has an unprecedented opportunity to develop a novel genetic medicine that could facilitate clinically meaningful patient benefit, Jerel A. Banks, MD, PhD, Benitecs executive chairman and CEO, said in a press release.

The preclinical studies will be done in partnership with a medicine and surgery team with several decades of experience in OPMD treatment, Benitec added.

The FDA granted orphan drug status to BB-301 as a potential OPMD treatment in January 2018. The EMA awarded it similar status in early 2017.

Jos is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimers disease.

Total Posts: 307

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

See the article here:
Final Tests Planned into Potential OCMD Gene Therapy, Could Support Trial in Patients - Muscular Dystrophy News

Posted in Gene therapy | Comments Off on Final Tests Planned into Potential OCMD Gene Therapy, Could Support Trial in Patients – Muscular Dystrophy News

Gene therapy drug priced at $2 million saves North Carolina babys life – WTKR News 3

Posted: September 26, 2019 at 8:41 am

Please enable Javascript to watch this video

NORFOLK, Va. -Kaeli Prices piercing cry is a joyful noise to her mom and dad.

She'll be screaming right in your face and all we can think is that we're just so thankful that we can hear her now, said Kelli Price, Kaelis mother.

When Kaeli was born in March, you could barely hear her cry and more signs signaled something wasnt right.

We started noticing she wasn't holding her head up like some babies would normally do, said her mother. So we started to worry a little bit.

Their pediatrician in Belvidere, North Carolina began to worry, too. He sent them to see Dr. Crystal Proud, a pediatric neurologist at Childrens Hospital of The Kings Daughters. The doctor specializes in Spinal Muscular Atrophy. Its the top genetic killer of infants.

The babies that were diagnosed with this disorder passed away from losing the ability to breathe because those muscles became so weak, explained Dr. Proud.

The doctor said the source of the disorder is a missing or mutated gene which keeps the babies muscles from developing. Most diagnosed with SMA die by the age of two. Ten babies a year are diagnosed with the deadly condition in Virginia. At just eight weeks old, testing confirmed Kaeli Price was one of them.

We were overwhelmed, said Kaelis mother.

We felt powerless, said Brandon Price, Kaelis father.

Dr. Proud started Kaeli on a drug called Spinraza, which has shown promise in babies with SMA since it was approved by the FDA in 2016. It requires an injection into their tiny bodies every four months for the rest of their lives.

Not long after Kaelis initial treatment on Spinraza, a newly approved gene therapy drug called Zolgensma hit the market. It would essentially give Kaelis body the missing gene, and it would only require one dose. However, the drug came with a price tag of $2.1 million. The Price familys insurance covered it, allowing Kaeli to be the first baby in Virginia to be treated with Zolgensma under FDA approval.

I can't even describe how thankful we are, said Mrs. Price.

I hope and I expect that she will sit, stand, and walk. She will go through school and just excel, said Dr. Proud. And at some point well down the road she will have her own family that she can tell the story to.

Zolgensma has come under scrutiny because of its multi-million dollar price tag.

Dr. Proud, who was part of the clinical trials for the gene therapy drug, said it is actually cost effective when you weigh the billions of dollars it takes for clinical trials and the medical bills a child would incur without the drug.

Dr. Proud said beginning this year, all newborns in Virginia will be tested for SMA. The earlier doctors can intervene, preferably within the first few weeks of life, the better their chances for treatment.

Continue reading here:
Gene therapy drug priced at $2 million saves North Carolina babys life - WTKR News 3

Posted in Gene therapy | Comments Off on Gene therapy drug priced at $2 million saves North Carolina babys life – WTKR News 3

7-year-old receives FDA-approved gene therapy – Newswise

Posted: September 26, 2019 at 8:41 am

MEDIA CONTACT

Available for logged-in reporters only

Newswise When Zion Grant was 3 months old his mother Daisy Dodd noticed he wasnt tracking her with his eyes. Zion would fixate on a light in the room, but not on her face.

Genetic testing confirmed Zion hadLeber congenital amaurosis, a rare eye condition that usually starts in childhood and worsens over time. Cells in the eye crucial for vision diminish, and by age 20, mostwith thisform of retinal dystrophy are legallyblind.

But Zions diagnosis would come during a period of hope and progress in the field of gene therapy aimed at curing blindness.

Progress in treating Leber congenital amaurosis is something physicians and families have long worked for through research andclinical trials.

Leber congenital amaurosisamaffects the retina, the tissue in the back of the eye that detects light and color. The condition occurs in 2 to 3 out of 100,000 newborns in the United States, according to theNational Institutes of Health.

Vision problems associated with the eye condition include night blindness and diminished visual fields.

With the boys diagnosis in mind, in 2014, Zions family moved from Tennessee to Michigan to establish a relationship with theretinal dystrophy clinicat theUniversity of Michigan Kellogg Eye Center, where clinical trials were underway and new treatments were on the horizon.

Kellogg is one of just 10 centers in the country to offerLuxturna, which in 2017 became the first genetherapy approved by the U.S. Food and Drug and Administration for an inherited disease.

In clinical trials, the treatment produced dramatic results, restoring the ability of patients to see things they couldnt see before, like stars in the night sky and their parents faces.

Moving back to Michigan and being introduced to the new therapy was a sign that we were in the right place, says Dodd. Our care team at Kellogg gave Zion the chance to see like a normal kid again, and we couldnt be more grateful.

Cagri Besirli, M.D., Ph.D.is Zions doctor and a Kellogg ophthalmologist who specializes in pediatric retinal illnesses.

These therapies are provided to our youngest patients so they do not have to endure more vision loss later in life, says Besirli. For many families, this genetic therapy gives them hope for the future.

The gene therapy process

Gene therapy provides a working copy of a gene responsible for producing a protein that makes light receptors work in the eye.

The gene therapy approved by the FDA was developed for those with a mutation in the RPE65 gene. Treatment involves surgery to inject a functioning copy of the gene directly under the retina using a fine needle. Zion received the first injection in early January and the second later that month.

I knew I had to do what was best for my kid, and giving him the best sight possible was what Zion needed the most, says Dodd. Thats why we went forward with the Luxturna treatment.

Kari Branham, M.S., a genetic counselor at Kellogg, worked with Zions family to help themunderstand the genetic basisfor Zions condition.

We have seen such amazing progress with these conditions over the last 15-20 years,says Branham. We used to tell patients and their families that we would have to wait and see what happens, but now we can actually do something to help.

By going through the gene therapy process, Branham says the team is hopeful that this has changed Zions prognosis.

The treatment is designed to stop or slow the death of specialized cells in the retina, called photoreceptors, that send visual information to the brain.

Patients who have Leber congenital amaurosis have night blindness, says Besirli. One of the first treatment effects after receiving Luxturna is that (patients) are telling us that they function much better in dark.

They can play outside much longer, they can navigate around the house and dont need nightlights anymore and can participate in indoor sports. Thats been a huge change in their lives.

Changing the trajectory

Seven months after treatment, Zion, now age 7, and his family are back to their normal routine in Montrose, Mich., and monitor his progress during follow-up appointments at Kellogg.

Zion says hes looking forward to playing football and, with improved vision -- playing outside at night with his brothers.

We hope that with Zion we have changed the trajectory for him to the point that in his 20s he wont have significant vision loss we see with him now, says Branham.

See more here:
7-year-old receives FDA-approved gene therapy - Newswise

Posted in Gene therapy | Comments Off on 7-year-old receives FDA-approved gene therapy – Newswise

Fennec Pharma names gene therapy exec to its board – WRAL Tech Wire

Posted: September 26, 2019 at 8:41 am

RESEARCH TRIANGLE PARK Fennec Pharmaceuticals Inc. has appointed Jodi Cook to its board of directors the company announced in a statement Tuesday.

Cook is currently the head of gene therapy for PTC Therapeutics Inc., a global biopharmaceutical company. Before beginning her work at PTC, she helped found Agilis Biotherapeutics, a clinical-stage company focused on gene therapies, where she also served as chief operating officer.

Jodi Cook

On behalf of the board of directors, we welcome theaddition of Jodi Cook, saidKhalid Islam, Fennecs chairman, in a press release. She brings extensive scientific, clinical and executive business experience to the Company. Her background and track record of success will enhance our team as we further advance the commercialization and development strategy of PEDMARK.

PEDMARK is a therapy intended to help children with hearing loss as a result of platinum-based chemotherapy. There is currently no preventative measure for this type of hearing loss. Fennec aims to complete its NDA submission for the treatment in early 2020 with a potential commercial launch of PEDMARK in the second half of 2020.

I am delighted to be joining Fennecs board of directors at this key point of development for PEDMARK, said Cook in the press release. Cisplatin induced hearing loss is a significant unmet medical need, a solution to which has evaded medicine for decades.

This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hills School of Media and Journalism.

More here:
Fennec Pharma names gene therapy exec to its board - WRAL Tech Wire

Posted in Gene therapy | Comments Off on Fennec Pharma names gene therapy exec to its board – WRAL Tech Wire

Global & US Gene Therapy Market 2019-2020: Immunodeficiency Syndromes – The Focus of Gene Therapy – PRNewswire

Posted: September 26, 2019 at 8:41 am

DUBLIN, Sept. 20, 2019 /PRNewswire/ -- The "Global & US Gene Therapy Market Forecast to 2020" report has been added to ResearchAndMarkets.com's offering.

Gene therapy is one of the most widely researched fields in the healthcare industry. The high potential of gene therapy to cure various chronic diseases makes it a popular research area. Various researches are being performed across the globe to explore the potential of gene therapy for the treatment of incurable diseases, such as diabetes, cancer, and HIV amongst others.

According to this new research report "Global & US Gene Therapy Market Forecast to 2020, most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up. Primarily, the gene therapy market is dominated by oncology applications, with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. Furthermore, the chapter also provides details regarding the various aspects of the clinical trials in the different gene therapy application by phases, vector types, etc.

The major part of the revenue of gene therapy market is generated from research phase. Most of the gene therapy products are in research phases, only few products have been commercialized till date. The report also provides the sales of major marketed gene therapy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms which are aiding them to develop new products. The study highlights the applications for which the investments have been received.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia, and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.

Gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry's growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understand the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction3.1 Classification of Gene Therapy Techniques3.2 Physical Methods of Gene Transfer3.2.1 Electroporation3.2.2 Hydrodynamic3.2.3 Microinjection3.2.4 Particle Bombardment3.2.5 Ultrasound-Mediated Transfection3.3 Vectors for Gene Therapy3.3.1 Viral Vectors3.3.1.1 Adenoviral Vectors3.3.1.2 Adeno-associated Virus Vectors3.3.1.3 Retroviral Vectors3.3.1.4 Lentiviral Vectors3.3.2 Non Viral Vectors3.3.2.1 Naked DNA/Plasmid Vectors3.3.2.2 Oligonucleotides3.3.2.3 Liposomes, Lipoplexes and Polyplexes3.3.2.4 Gene-Activated Matrix

4. Industry Overview4.1 Market Drivers4.1.1 Failure of Conventional Therapies to Treat Cancers4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations 4.1.3 Rising Incidence of Chronic and Life-Threatening Diseases4.1.4 Growing Interest of Venture Capital Firms4.2 Market Restraints4.2.1 Stringent Regulatory Laws & Safety Concerns 4.2.2 Challenges in Commercialization of Gene Therapy4.2.3 High Cost of the Gene Therapy Drugs4.2.4 Pitfalls in Current Technique4.2.5 Production & Manufacturing: A Unique Challenge for Gene Therapies 4.3 Market Opportunities4.3.1 Approval of Gene Therapy Drug in Europe4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity 4.4 Industry Trends4.4.1 Gene Silencing: Gaining Momentum4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy4.4.4 Nanotechnology: Empowering Gene Therapy4.4.5 Gene Therapy: A New Hope to Treat Blindness4.4.6 Gene Therapy: Potential Cure for Cancer4.5 Winning Imperatives4.5.1 Investment in R&D Activities

5. Clinical Trial Assessment & Pipeline Analysis5.1 Clinical Trials5.1.1 By Geography5.1.2 By Indication5.1.3 By Gene Type5.1.4 By Vector5.1.5 By Clinical Trial Phase5.2 Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario6.1 Regulatory Landscape6.1.1 US6.1.2 Canada6.1.3 Europe 6.1.4 Japan6.1.5 China6.1.6 India6.1.7 Australia6.2 Reimbursement Scenario in Global Market

7. Marketed Gene Therapies7.1 Neovasculgen7.2 Glybera7.3 Gendicine, Rexin-G, Oncorine7.3.1 Gendicine7.3.2 Rexin G 7.3.3 Oncorine

8. Gene Therapy Market8.1 Global8.2 US

9. Gene Therapy Market by Application9.1 Oncology9.1.1 Clinical Trials 9.1.2 Prevalence9.1.3 Market Outlook9.2 Cardiovascular Diseases9.3 Infectious Diseases9.4 Neurological Diseases9.5 Genetic Diseases9.6 Others

10. Gene Therapy Market Size by Geography10.1 North America10.2 Europe10.3 Asia10.4 Rest of the World (RoW)

11. Competitive Landscape11.1 Strategies Adopted by Various Players11.1.1 Strategic Collaborations11.1.2 Acquisitions 11.1.3 Funding & Investments11.2 Companies Progress in Gene Therapy In 2015

12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)12.1 Spark Therapeutics, LLC12.2 ViroMed Co. Ltd. dba VM BioPharma12.3 Advantagene Inc.12.4 Bluebird Bio12.5 Sanofi12.6 Vical Inc.12.7 Oxford BioMedica Plc12.8 Genethon12.9 uniQure N.V.12.10 Human Stem Cells Institute12.11 Shanghai Sunway Biotech Co. Ltd.12.12 Sibiono GeneTech Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/g01of6

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Follow this link:
Global & US Gene Therapy Market 2019-2020: Immunodeficiency Syndromes - The Focus of Gene Therapy - PRNewswire

Posted in Gene therapy | Comments Off on Global & US Gene Therapy Market 2019-2020: Immunodeficiency Syndromes – The Focus of Gene Therapy – PRNewswire

Page 1,354«..1020..1,3531,3541,3551,356..1,3601,370..»